Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry

J Thromb Thrombolysis. 2024 Jan;57(1):178. doi: 10.1007/s11239-023-02904-9.

Wern Yew Ding¹, Ameenathul Mazaya Fawzy¹, Giulio Francesco Romiti^{1

2}, Marco Proietti^{1

3

4}, Daniele Pastori^{1

5}, Menno V Huisman^{1

6}, Gregory Y H Lip^{7

8}, Ameenathul Mazaya Fawzy¹; GLORIA-AF Investigators

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
² Department of Translational and Precision Medicine, Sapienza - University of Rome, Rome, Italy.
³ Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.
⁴ Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
⁵ Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
⁶ Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
⁷ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. gregory.lip@liverpool.ac.uk.
⁸ Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark. gregory.lip@liverpool.ac.uk.

No abstract available

Publication types